Clinical trials: Advanced Solid Cancer
Melanoma, Head and Neck Squamous Cell Carcinoma
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours.
- Conditions
- Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT06305247
- Testing
- IPN01194
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 36 people
- Sponsor
- Ipsen
Advanced Solid Tumor
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetics and treatment effect of CS1001 in combination with Donafenib in patients with advanced solid tumors.
- Trial name
- NCT04472858
- Testing
- Donafenib, CS1001
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05877599
- Testing
- NT-175
- Where
- 20 sites in United States
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
The purpose of this study is to evaluate the safety and activity of BPX-601 CAR-T cells in participants with previously treated advanced solid tumors (prostate) expressing high levels of prostate stem cell antigen (PSCA).
- Trial name
- NCT02744287
- Testing
- BPX-601, Rimiducid
- Where
- 13 sites in United States
- Volunteers
- 52 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumors
Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors
Study of ABT-869 in Combination with Tarceva in Subjects with Solid Tumors
- Trial name
- NCT00754104
- Testing
- ABT-869, Tarceva
- Sponsor
- Abbott
Malignant Solid Tumor
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ZL-1218 as a single agent and as combination therapy in subjects with…
- Trial name
- NCT05859464
- Testing
- ZL-1218, Pembrolizumab
- Where
- 15 sites in United States, China and 1 more
- Volunteers
- 34 people
- Sponsor
- Zai Lab (Hong Kong), Ltd.
HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC)
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1…
- Conditions
- HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
- Trial name
- NCT07029399
- Testing
- NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole
- Where
- 18 sites in United States
- Volunteers
- 361 people
- Sponsor
- NiKang Therapeutics, Inc.
Malignant Solid Tumor, Lymphomas
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
Phase 1 study to determine safety, tolerability, dose-limiting toxicities (DLTs), and recommended Phase 2 dose of AV-299 administered IV as monotherapy to patients with relapsed or refractory solid tumors, lymphoma, or multiple…
- Conditions
- Malignant Solid Tumor, Lymphomas, Multiple Myeloma
- Trial name
- P05538 (NCT00725634)
- Testing
- AV-299, AV-299 + erlotinib
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Solid Tumor, Advanced Cancer
Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
The purpose of this study is to evaluate the response of toripalimab (JS001), a PD1 antibody, in participants with POLE or POLD-mutated and non microsatellite instability (non-MSI-H) advanced solid cancers.
- Trial name
- NCT03810339
- Testing
- Toripalimab
- Where
- 4 sites in China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumors
Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
This is an open-label, study of MEDI9090 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of MEDI9090 in adult subjects with advanced solid tumors.
- Trial name
- NCT02900157
- Testing
- MEDI9090, Durvalumab
- Where
- 8 sites in United States, Japan
- Volunteers
- 42 people
- Sponsor
- MedImmune LLC
Solid Tumor
Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
This is an Investigator-initiated, Open-Label Clinical Study of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination with anti-PD-1 monoclonal antibody in Patients with Advanced Solid Tumors.
- Trial name
- NCT07245901
- Testing
- circFAM53B mRNA vaccine, toripalimab
- Volunteers
- 60 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Advanced Solid Tumors
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
The primary objectives of this study are to: Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors Determine the recommended phase 2 dose…
- Trial name
- NCT06131398
- Testing
- AMG 355, Pembrolizumab
- Where
- 25 sites in United States, Australia and 9 more
- Volunteers
- 77 people
- Sponsor
- Amgen
Solid Tumor
A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors
This Phase 1a, single center, open-label, repeat dose study will evaluate the safety, efficacy, and Pharmacokinetics of ascending doses of OBP-801 in patients with advanced solid tumors.
- Trial name
- NCT02414516
- Testing
- OBP-801
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Oncolys BioPharma Inc
Advanced Solid Tumors
Study of TP-3654 in Patients With Advanced Solid Tumors
TP-3654 is an oral PIM inhibitor. This is a Phase 1, open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum tolerated dose (MTD) and dose-limiting toxicities…
- Trial name
- NCT03715504
- Testing
- TP-3654
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Sumitomo Pharma America, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer
A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients
The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of WX-0593 alone in the treatment of advanced cancer.
- Trial name
- NCT03389815
- Testing
- WX-0593 Tablets
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00008125
- Testing
- filgrastim, carboplatin, docetaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pittsburgh
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard…
- Conditions
- Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC
- Trial name
- NCT05859074
- Testing
- MQ719, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
This phase I trial is studying the side effects and best dose of sorafenib and bortezomib in treating patients with advanced cancer.
- Conditions
- Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma, Stage IV Chronic Lymphocytic Leukemia
- Trial name
- NCT00303797
- Testing
- 17-N-allylamino-17-demethoxygeldanamycin/bortezomib, sorafenib tosylate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Tumors
A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers
The main objective of this study is to evaluate the Effect of Food on the Pharmacokinetics of CM082 tablet.
- Trial name
- NCT04126668
- Testing
- CM082 with fed or fasting
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AnewPharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.